The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

TB-500 Fragment 1-4

Research chemical · Grade C

Goals
muscle, beauty
Evidence
—
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

TB-500 Fragment 17-23

Research chemical · Grade C

Goals
healing, muscle
Evidence
0 RCT / 4 animal / 0 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Epitalon

Bioregulator · Grade C

Goals
cognition, sleep, longevity
Evidence
0 RCT / 5 animal / 3 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

TB-500

Research chemical · Grade C

Goals
healing, muscle, beauty
Evidence
1 RCT / 6 animal / 1 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
hard-stop
Typical dose
Loading: 2-5 mg twice weekly x 4-6 weeks. Maintenance: 2 mg weekly or biweekly. SubQ, no site preference required.
Half-life
Estimated half-life of TB-500: 24-36 hours (estimated
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →